MedTrace Logo

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

NCT05156970 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2025-07-31

No results posted yet for this study

Summary

This study is the first clinical study of first-line treatment of head and neck squamous cell carcinoma with drugs targeting VEGF signaling pathway combined with PD-1 inhibitors in China, which explores the new combination therapies urgently needed in clinical practice and lays a foundation for subsequent studies, with important scientific research significance and clinical value.

Conditions

  • Recurrent Head and Neck Squamous Cell Carcinoma
  • Metastatic Head and Neck Squamous Cell Carcinoma

Interventions

DRUG

Camrelizumab

Camrelizumab 200 mg IV on Day 1 of each 3-week cycle for up to 24 months

DRUG

Cisplatin

Cisplatin 75 mg/m\^2 or Carboplatin AUC5 IV on Day 1 of each 3-week cycle (4 to 6 cycle maximum)

DRUG

Docetaxel

Docetaxel 75 mg/m\^2 IV on Day 1 of each 3-week cycle (4 to 6 cycle maximum)

DRUG

Apatinib Mesylate

Apatinib 250mg qd for up to 24 months

DRUG

Carboplatin

Carboplatin at a target AUC 5 IV on Day 1 of each 3-week cycle (6 cycle maximum)

Sponsors & Collaborators

  • Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

    lead OTHER

Principal Investigators

  • Chenping Zhang, M.D. · the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-24
Primary Completion
2024-06-24
Completion
2025-06-24

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05156970 on ClinicalTrials.gov